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Abstract The identification of the hexanucleotide repeat ex- 
pansion (HRE) GGGGCC (G4C2) in the non-coding region 
of the C9ORF72 gene as the most frequent genetic cause of 
both amyotrophic lateral sclerosis (ALS) and frontotemporal 
dementia (FTD) has opened the path for advances in the 
knowledge and treatment of these disorders, which remain 
incurable. Recent evidence suggests that HRE RNA can cause 
gain-of-function neurotoxicity, but haploinsufficiency has al- 
so been hypothesized. In this review, we describe the recent 
developments in therapeutic targeting of the pathological ex- 
pansion of C9ORF72 for ALS, FTD, and other neurodegen- 
erative disorders. Three approaches are prominent: (1) an an- 
tisense oligonucleotides/RNA interference strategy; (2) using 
small compounds to counteract the toxic effects directly 
exerted by RNA derived from the repeat transcription (foci), 
by the translation of dipeptide repeat proteins (DPRs) from the 
repeated sequence, or by the sequestration of RNA-binding 
proteins from the C9ORF72 expansion; and (3) gene therapy, 
not only for silencing the toxic RNA/protein, but also for 
rescuing haploinsufficiency caused by the reduced transcrip- 
tion of the C9ORF72 coding sequence or by the diminished 
availability of RNA-binding proteins that are sequestered by 
RNA foci. Finally, with the perspective of clinical therapy, we 
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discuss the most promising progress that has been achieved to 
date in the field. 
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Introduction 
 
Amyotrophic lateral sclerosis (ALS) is an incurable and in- 
variably fatal neurodegenerative condition characterized by 
the progressive loss of both upper and lower motor neurons 
in the cortex, brainstem, and spinal cord; it clinically results in 
progressive paralysis and death within 3–5 years of its onset, 
often due to respiratory failure [1]. No effective therapy is 
available for this disease. The only drug approved by the 
FDA and EMA is riluzole, which extends the median lifespan 
by only 3 months [1]. Thus, the discovery of clinically effec- 
tive therapies is urgently needed. The vast majority of cases 
are sporadic (sALS) of unknown origin, while 5–10 % are 
familial (fALS), often with autosomal dominant inheritance 
[2]. The disease pathogenesis is multilayered, given that sev- 
eral pathways have been identified as key elements both in the 
onset and in the progression of the disease. Although several 
elements have been investigated as possible targets for treat- 
ment advancement, the lack of a clear understanding of the 
causes of ALS, particularly in cases of sALS, has hampered 
the search for a cure [1]. However, the genetic forms of ALS 
can offer a solid basis for research since, at least in these cases, 
the etiopathogenic primum movens is known. The first caus- 
ative genetic mutations were described in Cu–Zn superoxide 
dismutase 1 (SOD1) gene in 1993 [3], and due to several 
genome sequencing projects, many of the genes responsible 
for ALS (>30 genes so far) have been described [4]. The 
identification of a hexanucleotide repeat expansion  (HRE) 
 
 
  
  
 
GGGGCC (G4C2 > 30) in the non-coding region of the hu- 
man chromosome 9 open reading frame 72 (C9ORF72) gene 
as the most frequent genetic cause of both ALS and 
frontotemporal dementia (FTD), and which is also present in 
other neurodegenerative diseases, has represented one of the 
major breakthroughs in the last 20 years of research in this 
field [5, 6]. In fact, the G4C2 HRE in the C9ORF72 gene is 
detected in as many as 40 % of fALS and FTD and in approx- 
imately 9 % of sALS cases, with further descriptions in other 
neurodegenerative disorders [5, 7–9]. This discovery has 
opened the path for progress in the knowledge and treatment 
of these devastating diseases. C9ORF72 HRE-linked patho- 
genesis has been suggested to be elicited by means of loss-of- 
function and toxic gain-of-function mechanisms that comprise 
the following: (1) transcribed sense GGGGCCexp or antisense 
(CCCCGGexp) RNAs that sequester proteins,   therefore 
interfering with their physiological function [8]; (2) sense or 
antisense expanded RNAs that are translated via repeat- 
associated non-AUG initiated (RAN) translation to generate 
toxic dipeptide repeat proteins (DPRs) [10–13]; or (3) 
haploinsufficiency that originates from diminished transcrip- 
tion of the C9ORF72 exonic sequence [14, 15] (Fig. 1). It is 
likely that these mechanisms are not mutually exclusive but 
correspond to the disease pathogenesis. Indeed, it has been 
described that HRE RNA forms hairpin and G-quadruplex 
structures that bind and sequester RNA-binding proteins 
(RBPs) [16, 17]. One of the proteins interacting with the 
G4C2 RNA is RanGAP1, a key regulator of nucleocytoplasmic 
transport. RanGAP (an orthologue of human RanGAP1 in 
Drosophila) physically links with HRE RNA, thereby 
compromising nuclear import and thus representing a possible 
central pathogenic event in ALS/FTD [18]. Indeed, DPRs can 
 
 
Fig. 1 Schematic representation of C9ORF72 pathogenic events in the 
nucleus and cytoplasm. I: C9 physiological translation and transcription. 
II: C9 pathological pathways. III: loss of translation of the C9 
hexanucleotide expanded allele, leading to haploinsufficiency and loss 
of function. IV: RNA toxicity is due to transcription of C9 HRE 
(hexanucleotide repeat expansion), leading to RNA with a G- 
quadruplex tertiary structure (IVa), which can form RNA foci (IVb) or 
interact with nuclear transporters (IVc). RNA foci (IVb) toxic pathways 
include the disruption of RNA splicing, interactions with RBPs (as 
TDP43, FUS, p62, PUR α, hnRNPA1, hnRNPA1B2, ADARB2),   and 
nucleolar stress. V: Protein toxicity is mediated by cytoplasmic translation 
of HRE containing RNA, leading to RAN translation of dipeptide repeat 
proteins (DPRs). The DPR toxic pathways include dipeptide-specific 
disruption of RNA splicing, nucleolar stress, ubiquitinated inclusions, 
ubiquitin-proteasome system (UPS) inhibition, and endoplasmic reticu- 
lum (ER) stress 
  
 
also affect the nucleocytoplasmic transport system; this has 
been demonstrated in yeast and more recently in Drosophila 
using an RNA interference library that targets proteins of the 
nuclear pore complex and other regulators, including RanGAP 
as a toxicity modifier [19, 20]. Bioinformatic analyses have 
demonstrated that glycine–arginine and proline–arginine re- 
peats may simulate the nuclear localization signals of these 
proteins and thus affect nuclear import by overloading the 
nucleocytoplasmic transport system [20]. These data further 
establish this secondary event as a possible treatment target. 
Overall, the pathways mentioned above may represent pos- 
sible therapeutic targets in ALS/FTD. If the disease is initiated 
by RNA foci and/or DPRs originating from the repeated ex- 
pansion, selectively blocking transcription and/or translation 
of the repeats might inhibit their negative effects. Remarkable 
advances have already been achieved in this direction, and 
they are presented in detail in this review. Briefly, antisense 
oligonucleotides/RNA interference sequences have been used 
to stimulate the elimination of pathological C9ORF72 tran- 
scripts [16, 21, 22] and the small compounds that are able to 
link the secondary structure of the repeat sequence, which can 
thereby limit the accumulation of RNA foci and toxic DPRs 
[23]. Indeed, short hairpin (sh) RNA or similar nucleotidic 
sequences, either naked or delivered with a viral vector, can 
be used for the same purpose. However, the haploinsufficiency 
that is due to reduced transcription of the C9ORF72 coding 
region or the loss of function of sequestered RBPs can be res- 
cued by gene transfer of wild-type genes. This article highlights 
the utility of targeting the known C9ORF72 disease pathways 
at multiple levels (Fig. 2). Furthermore, we discuss the recent 
therapeutic advances from the perspective of clinical 
translation. 
 
 
Oligonucleotide/RNA Interference-Based 
Therapeutic Strategies 
 
Antisense Oligonucleotides 
 
Antisense oligonucleotides (ASOs) are short oligonucleotidic 
sequences that can interfere with RNA processing/ 
transduction in many different ways. The consequence of 
complementary matching can either be the destruction of the 
messenger RNA (mRNA) of interest with the induction of H/ 
L RNAse or the prevention of the interaction with RBPs 
through steric blocking, thereby preventing its splicing/ 
processing without degradation. Both mechanisms can lead 
to a decreased level of gene expression for the target protein 
[16, 24–26]. This strategy is certainly advantageous if the 
pathogenesis of neurodegeneration is sustained by Ba gain- 
of-toxic-function protein^; conversely, if the expansion causes 
a loss of normal protein activity, this approach may not be 
completely safe. 
There are three C9ORF72 (C9) transcripts in humans: var- 
iant 1 (exons 2–5) encoding a 222-aa isoform defined as C9 
short (C9-S) and variants 2 and 3 (exons 2–11) encoding a 
481-aa isoform defined as C9 long (C9-L) [27]. The HREs are 
located in the promoter region of variant 2 and the first intron 
of variants 1 and 3. The presence of three different C9ORF72 
transcripts suggests a need for a selective molecular approach. 
For example, high levels of the C9ORF72 variant V1 have 
recently been associated with a longer survival, which sug- 
gests that ASOs should not be designed to alter all C9ORF72 
expressions [28]. 
Recent advances in the production of ASO molecules have 
been made that increase their stability, cell penetration, and 
targeting of RNA [29]. The feasibility of this approach is 
supported by data that were obtained from the first clinical 
trial assessing the safety, tolerability, and pharmacokinetics 
of ASOs; in this trial, ASOs targeting the SOD1 mRNA 
(ISIS 333611) were injected intrathecally in mutated ALS 
subjects [30]. 
The role of sequestration of RBPs seems to be crucial for 
the disease pathogenesis, not only in ALS but also in other 
neuromuscular disorders. Repeat-specific ASOs that are able 
to block the binding of specific RBPs, preventing their segre- 
gation in RNA foci, show therapeutic promise for myotonic 
dystrophy 1 (DM1), the neuromuscular disease in which the 
pathological roles of nucleotide repeat expansion and RNA 
foci were reported for the first time [31]. Treatment with 
ASOs in in vitro C9ORF72 models showed a positive effect 
on RNA foci, causing their reduction in fibroblasts and in 
induced (i) neurons (neurons obtained from direct 
reprogramming of fibroblasts in patients) derived from 
C9ORF72-mutated patients [21]. Interestingly, the ASOs test- 
ed in these studies [21, 22] were designed to bind DNA sites 
that were located before and after the repeat, and the mole- 
cules formed at both of these sites reduced the presence of 
RNA foci, even though the binding site after the repeat also 
led to a depletion of total C9ORF72 RNAs. Regarding the 
potential effects of completely silencing C9ORF72, studies 
conducted in adult mice demonstrated that the long-term re- 
duction of C9orf72 RNAs is well tolerated without neuropath- 
ological or behavioral defects. However, data obtained in low- 
er species such as zebrafish and in Caenorhabditis elegans 
suggest that C9ORF72 loss of function can lead to motor 
defects [14, 32]. These differences could be the consequence 
of a species-specific tolerance to the deprivation of C9ORF72 
homologues or could be the result of dissimilar methods used 
to decrease the expression of C9ORF72, such as genetic 
knockdown versus the use of ASOs. A description of a patient 
carrying a homozygous C9ORF72 repeat expansion who did 
not show a more severe phenotype suggests that the loss-of- 
function hypothesis for C9 pathogenesis is less probable or, at 
least, not the predominant mechanism [33]. The function of 
the C9ORF72 gene is still largely unknown, so despite  the 
  
 
 
Fig. 2 Schematic representation of the therapeutic approaches and their 
subcellular interactions. In yellow: antisense oligonucleotide (ASO) therapy 
is able to act either by regulating splicing or by regulating translation with an 
RNAse H-dependent pathway or via steric block. In green: small molecules 
such as TMPyP4 and KPT-276 can be used to restore nuclear cytoplasmic 
physiological export–import of factors, which appear to be dysregulated in 
C9 pathology toward an import deficit and an increased export. TMPyP4 
can also act by interfering with the formation of an RNA G-quadruplex 
tertiary  structure. Salubrinal  and  TUDCA  can prevent endoplasmic 
reticulum (ER) stress, an unfolded protein response, and oxygen radical 
formation, leading to the inhibition of apoptosis. In red: a gene therapy 
approach utilizes viral vectors to carry genetic material. It can be used to 
prevent the unacceptable loss of the C9 mutated allele by replacing the 
defective one. Gene therapy can also be used to reduce the cytoplasmic 
translation of HRE containing RNA using an RNA interference (RNAi) 
strategy. Moreover, it can also be used to perform the so-called Breplacement 
strategy^ to ensure the presence of wild-type transcripts after C9 therapeutic 
knockout (Color figure online) 
 
argument outlined above, the safety of blocking protein ex- 
pression through ASO-based treatments must be carefully 
evaluated. The possibility of bidirectional transcription of 
the repeats should also be considered in the design of ASOs 
that have to target both sense and antisense strands [21]. 
In in vivo models of spinal muscular atrophy (SMA), another 
genetic motor neuron disease, amelioration of the disease pheno- 
type was achieved through the use of ASOs that interact with the 
splicing regulator molecules, either by blocking splicing suppres- 
sors or by promoting splicing activators [34–36]. Clinical trials 
testing the safety and efficacy of ASOs in humans are in progress 
to bring this treatment to SMA patients [37]. The results from a 
phase 1 study of nusinersen (ISIS-SMNRx ASO) in children 
with SMA have recently been published and support the contin- 
ued development of this strategy for the treatment of SMA [38]. 
Nuclear RNA foci can segregate proteins involved in RNA 
splicing and regulation, leading to splicing alteration and, con- 
sequently, the production of truncated, low-functioning 
proteins. 
So far, splicing alterations have not been clearly recognized 
in tissues or cells carrying mutated C9ORF72, but the segre- 
gation of RBPs in RNA foci provides powerful evidence for 
an aberrant splicing mechanism in C9ORF72 pathogenesis 
[16]. Hence, amelioration of the disease phenotype and neu- 
roprotection may be achieved by influencing the pathways 
involved in the aberrant splicing process. 
Recent studies have provided evidence for an HRE RNA 
gain-of-function mechanism, and to detect which of the can- 
didate RBPs modified G4C2-mediated neurodegeneration, a 
study in a Drosophila model expressing G4C2 30    repeats 
  
 
(G4C2)30 was performed [18]. In this system, the 
mislocalization of RanGAP leads to an alteration in the nucle- 
ar import and this can be preserved and implemented by an 
interaction between antisense oligonucleotides and small mole- 
cules (please see next paragraph) and the HRE G-quadruplexes. 
These data demonstrate the utility of ASOs in rescuing 
nucleocytoplasmic transport. 
Sense or scrambled ASOs targeting the C9orf72 RNAwere 
used in C9-ALS reprogrammed neurons to assess whether 
they were able to restore the observed alteration of the 
nuclear/cytoplasmic Ran (ras-related nuclear protein) gradient 
[21, 22]. Ran is a small GTP-binding protein belonging to the 
RAS superfamily that is crucial for the translocation of RNA 
and proteins through the nuclear pore complex. Ran is present 
in the cell as two different nucleotide-bound forms: (1) GDP- 
bound, the form that can enter the nucleus, and (2) GTP- 
bound, the form that can exit the nucleus. The conversion of 
RanGDP into RanGTP in the nucleus is mediated by the ac- 
tivity of RCC1, the nucleotide exchange factor for Ran. RCC1 
is also called Ran guanine nucleotide exchange factor 
(RanGEF). In the cytoplasm, the intrinsic GTPase activity of 
Ran that converts RanGTP into RanGDP is activated by bind- 
ing with Ran GTPase-activating protein (RanGAP) and is 
facilitated by the link with Ran-binding protein (RanBP). 
Thus, GTPase activation gives rise to the conversion of 
RanGTP into RanGDP, closing the BRan nuclear/cytoplasmic 
cycle^ [21, 22]. 
In C9ORF72 neurons undergoing sense strand ASO treat- 
ment, RNA foci were significantly reduced and the altered 
nucleocytoplasmic Ran gradient was restored, suggesting that 
the nucleocytoplasmic transport impairment was caused by 
C9ORF72 sense strand toxicity [18]. The same cellular 
models showed an increase of both the nucleocytoplasmic 
Ran and TAR DNA-binding protein 43 (TDP-43) gradients. 
In vivo, nuclear import alterations caused by G4C2 repeats 
were suppressed by ASOs. In fact, an ASO introduced into 
the food of Drosophila larvae co-expressing (G4C2)30 and 
NLS–ΔNES–GFP (a GFP reporter under nuclear localization 
signals (NLS) and without nuclear export signals (NES)) de- 
creased the nuclear mislocalization of NLS–ΔNES–GFP 
[18]. 
Overall, using an ASO strategy, it is possible to posi- 
tively target the different pathways that are implicated in 
C9ORF72 disease. Encouraging results have been pub- 
lished with regard to the pharmacological safety and toler- 
ability profile of the ASO approach. An ASO trial against 
the C9ORF72 expansion is in development and is expected 
to begin in late 2016. Thus, the next crucial step is to 
clearly understand the function of the c9orf72 protein and 
the risks related to its silencing or, as an alternative, to 
implement ASO strategies that do not cause any modifica- 
tion to the wild-type gene expression to safely translate this 
approach to the clinic. 
RNA Interference Strategy 
 
An alternative therapeutic approach against RNA-mediated 
toxicity is represented by the RNA interference (RNAi) strat- 
egy [39]. Similar to ASOs, the use of RNAi in the three most 
common therapeutic approaches (short interference RNAs 
(siRNAs), shRNAs or artificial microRNAs (miRNAs)) leads 
to a degradation of RNA transcripts of the target gene. Both 
the wild-type and the mutant allele are usually targeted with- 
out any distinction [39, 40]. Similar to the ASO strategy, this 
approach appears to be more appropriate in gain-of-function 
conditions and requires knowledge of the role and the function 
of the protein because it suggests a potential reduction/loss of 
protein that could be unsafe for cell survival and normal func- 
tion. An RNAi approach that is based on targeting a dominant 
mutant gene has been studied and applied with promising 
results to other neurodegenerative disorders, such as 
Parkinson’s disease, Alzheimer’s disease, and Huntington’s 
disease [40–42]. However, the mutant and normal allele are 
often quite similar, only differing in a few nucleotides, so the 
design of an allele-specific RNAi strategy might be difficult. 
To overcome these difficulties, a Breplacement strategy^ has 
been proposed (see also the gene therapy paragraph), in which 
the wild-type gene function is restored by means of designed 
wild-type genes that are not affected by the activity of RNAi 
after the inhibition of both mutants and normal alleles using 
RNAi [43]. Successful results were obtained using this strat- 
egy in vitro for other disease genes [43], but further studies are 
needed to evaluate the effect of the overexpression of the 
replaced protein as well as the safety and efficacy of the trans- 
fection method. In fact, one of the major challenges in the use 
of the RNAi strategy is how to avoid off-target toxicity that is 
generally induced by the cellular antiviral response after the 
delivery of these molecules. Recently, lipid nanoparticles were 
demonstrated to have high delivery efficiency with little tox- 
icity in the central nervous system (CNS) [44]. 
 
 
 
Small Molecule Therapeutic Approaches 
 
Another possible strategy to target the pathogenetic mecha- 
nisms of ALS associated with C9ORF72 expansion is based 
on the use of small molecules and is aimed at reducing the 
toxicity derived from both RNA foci and RAN translation. 
As we mentioned earlier, in repeat expansion diseases, 
RNA foci are often involved in sequestering cellular proteins, 
causing their dysfunction. For example, in DM1, the prefer- 
ential target is muscleblind (MBNL), a splicing modulator. In 
contrast, C9ORF72-RNA foci seem to bind several proteins 
that are mostly involved in forming the nuclear pore complex 
and regulating nucleocytoplasmic trafficking [45]. A recent 
study suggests that the main C9ORF72 expansion target could 
  
 
be RanGAP1, a protein that enhances nuclear import, acting 
on RanGTPase [18]. 
In vitro studies have demonstrated that the upregulation of 
RanGAP and importin α can rescue nucleocytoplasmic traf- 
ficking, while the overexpression of proteins such as RanGEF 
and exportin, which have the opposite activity, can enhance 
neurodegeneration. In this context, KPT-276 compound, 
which inhibits exportin 1, improved nuclear import [18]. 
RanGAP1 has been found to be preferentially bound by sense 
strand HRE with a G-quadruplex tertiary structure; thus, the 
cationic 5,10,15,20-tetra(N-methyl-4-pyridyl) porphyrin 
(TMPyP4), a porphyrin that disrupts this type of structure, 
was successfully applied, reducing RanGAP1 sequestration 
in RNA foci in vitro and ameliorating nucleocytoplasmic 
transport in Drosophila model [18]. TMPyP4 has already 
been shown to destabilize the G-quadruplex of both the 
DNA and the RNA (CGG)n repeats of the FMR1 gene, which 
is linked to human pathological conditions such as fragile X 
syndrome and fragile X-associated tremor ataxia [46]. 
TMPyP4 could be particularly important if a specific target 
of r(GGGGCC)n RNA is not found because it is also able to 
prevent the sequestration of other proteins, such as hnRNPA1 
and ASF/SF2, by C9ORF72-HRE [47]. 
Another pathological mechanism associated with mutant 
C9ORF72 is represented by RAN translation leading to 
DPRs: poly(GA) and poly(GR) from sense G4C2 repeats, 
poly(PR) and poly(PA) from antisense G2C4 repeats, and 
poly(GP) proteins from both sense and antisense transcripts 
[11]. In a Drosophila model expressing RAN, Freibaum and 
colleagues identified 18 genetic modifiers that belong to the 
nuclear pore complex. They also observed alteration in the 
nuclear envelope and RNA nuclear retention [45]. Poly(GA) 
has been proven to be neurotoxic, being highly aggregation 
prone and forming ubiquitin and p62-positive cytoplasmic in- 
clusions [48]. Recently, DPR toxicity has been studied in a 
mouse model, demonstrating that proteins involved in the deg- 
radation of the proteasome and in nucleocytoplasmic transport 
are sequestered by poly(GA). In particular, RanGAP1 was 
shown to colocalize with poly(GA) inclusions [48]. Inhibiting 
the ubiquitin–proteasome–system (UPS), RAN poly(GA) indi- 
rectly induces endoplasmic reticulum (ER) stress, as marked by 
PERK–CHOP pathway activation, thus leading to upregulation 
of the GADD34–PP1C complex and cell death [48]. Salubrinal, 
an inhibitor of this complex, has been found to reduce ER stress 
and enhance cell survival in neurons expressing poly(GA). This 
drug prevents GADD34/protein phosphatase 1 (PP1) from de- 
phosphorylating eukaryotic translational initiation factor 2α 
(eIF2α), which thus reduces protein synthesis and ER stress 
[49] and inhibits oxidative stress and apoptosis. Salubrinal has 
been applied with promising results to several medical research 
fields, in which ER stress is involved, such as brain injury and 
toxic damage [49–51]. Its neuroprotective activity resulted in 
the prevention of neuronal cell loss in    neurodegenerative 
processes and has also been tested in in vivo animal models 
expressing mutant TDP-43 protein, in which the positive effects 
of salubrinal were not fully explained by its known mechanism 
of action, thus suggesting other potential pathways for future 
study [52]. Thus, even if the primary mechanism underlying the 
cytoprotection by salubrinal seems to be the inhibition of eIF2α 
dephosphorylation, other types of pharmacological activity that 
can lead to off-target effects remain to be identified [53]. 
Another compound that provides neuroprotection, decreas- 
ing ER stress, is tauroursodeoxycholic acid (TUDCA), a chem- 
ical chaperone [54]. TUDCA is the taurine conjugate of 
ursodeoxycholic acid (UDCA); UDCA is approved by the 
FDA as a treatment for some cholestatic liver diseases and is 
used in traditional Chinese medicine, where it is obtained from 
the Asian bear [55]. TUDCA plays an important role in the 
inhibition of apoptosis due to its activity on mitochondria and 
unfolded protein responses and its ability to reduce ER stress 
and oxygen radical formation [56]. For these reasons, TUDCA 
has been successfully studied as a potential drug for several 
degenerative pathologies, such as Alzheimer’s, Parkinson’s, 
and Huntington’s diseases. A recent double-blind placebo-con- 
trolled clinical trial led in a cohort of ALS patients has demon- 
strated a reduction of disease progression in treated subjects 
[55]. Thus, ALS has been identified as a potential target for 
TUDCA [56]. 
The studies about salubrinal and TUDCA in C9ORF72- 
ALS also provide evidence that poly(GA) aggregates can con- 
tribute to neurodegeneration, independent of the presence of 
RNA foci. 
Small molecules acting upstream of RAN products were 
identified as compounds 1a, 2, and 3 and have recently been 
tested in a study led by Su and colleagues (2014). All three of 
the molecules were found to reduce RNA foci formation in 
(G4C2)66 cells. Specifically, compound 3 decreases poly(GP), 
while both poly(GP) and poly(PR) are markedly reduced by 
molecules 1a and 2. Moreover, 1a is also active in patient- 
derived i-neurons. Poly(GP) was found to be a detectable mark- 
er in C9ORF72-ALS cerebrospinal fluid (CSF), an aspect that 
could be a useful marker for diagnosis, for correlation studies 
about disease severity or progression, and for therapy monitor- 
ing [23]. 
Among the DPRs, poly(GR) was the most toxic in both 
Drosophila and mammalian models [19]. Genetic screening 
identified several proteins that can rescue DPR toxicity, such as 
karyopherins, MTR10, which encodes a receptor involved in 
nuclear import, and NDC1, a relevant component of the nuclear 
pore complex. In contrast, the authors confirmed that analogues 
of RanGEF enhance poly(PR) toxicity. Another DPR toxicity 
modifier is NSR1, the yeast analogue of nucleolin, an important 
nucleolar protein that binds C9ORF72-HRE, and this in line with 
the fact that rRNA processing is involved in DPR pathology [17]. 
Because there is evidence that epigenetic alterations are 
involved in C9 pathologies, they could be an interesting target 
  
 
for small molecules. In fact, all three transcriptional variants of 
C9ORF72 seem to be reduced in patients’ tissues as a possible 
consequence of the promoter’s hypermethylation of CpG 
islands and as a result of the HRE’s hypermethylation itself 
in the expanded allele [57–59], thus leading to a potentially 
deleterious condition of haploinsufficiency. The role of epige- 
netic processes has already been studied in other repeat ex- 
pansion disorders, such as Fragile X-associated Tremor/ 
Ataxia Syndrome (FXTAS), in which the overexpression of 
FMR1 mRNA can be reversed by histone acetyltransferase 
(HAT) inhibitors [60]. Zeir and colleagues (2015) have recent- 
ly studied the activity of bromodomain proteins in C9ORF72- 
ALS. The bromodomain extra terminal (BET) family binds 
acetylated histones. Specifically, BRD3 was identified as an 
epigenetic regulator of C9ORF72 expression. Inhibiting 
BDR3 in C9ORF72-ALS patient fibroblasts resulted in in- 
creased levels of the three C9ORF72 transcriptional variants 
[61]. BRDs share a conserved fold or Bpocket^ that comprises 
a left-handed bundle of four alpha helices (αZ, αA, αB, αC) 
that are linked by highly variable loop regions (ZA and BC 
loops), which form the rim of the substrate-binding pocket and 
determine the degree of substrate recognition [62]. Among the 
BET inhibitors, the most studied are JQ1 [63] and IBET-762, 
both of which interact with the BRD pocket in competition 
with acetylated peptide binding. However, despite several on- 
going clinical trials [64], no BRD inhibitor has so far been 
approved by the FDA. 
Belzil and colleagues (2013) revealed that histone H3 and 
H4 in the expanded C9ORF72-allele are trimethylated at ly- 
sines 9 (H3K9), 27 (H3K27), 79 (H3K79), and 20 (H4K20) 
and that the DNA and histone demethylating agent 5-aza-2- 
deoxycytidine (5AZA) can increase C9ORF72 mRNA ex- 
pression [57]. 
Small molecules represent a key strategy to address the 
multiple pathogenetic mechanisms of ALS that are associated 
with the C9ORF72 repeat expansion because they can be spe- 
cifically targeted, thus leading to a better understanding of the 
cellular pathological pathways involved, and because they can 
enhance neuroprotection, restoring cell physiological func- 
tions. Epigenetics is an interesting field of investigation for 
discovering potentially characteristic patterns as markers of 
pathology and for modulating C9ORF72 expression. 
 
 
Gene Therapy for C9ORF72 
 
The term gene therapy refers to the cellular delivery of a stable 
polymer of nucleic acids that modifies the cellular genome by 
an integrating or non-integrating mechanism, leading to the 
transcription of new genes. Once translated, the new genes can 
take part in different pathways according to the therapeutic 
purpose of the engineered sequence. In this context, for dis- 
eases that are characterized by loss of function, it is possible to 
deliver wild-type genes to supply the missing function of the 
mutated sequence. In addition, for diseases that are character- 
ized by gain of function, it is possible to deliver genes 
encoding regulatory peptides or nucleotides such as for 
RNAi. Gene silencing could therefore be combined with a 
replacement therapy, thus preventing the consequences that 
may be derived from the total loss of the gene function. This 
approach is more likely to be suitable in the case of C9ORF72. 
One crucial aspect of gene therapy is the delivery of the 
gene in the CNS using a strategy that is effective but not 
invasive. Among the DNA-based viral vectors, adeno- 
associated viruses (AAVs) are a group of single-stranded 
DNA viruses that are highly promising for use in gene therapy 
for neurological diseases. In fact, specific serotypes, such as 
AAV9 and AAV6, can cross the hematoencephalic barrier in 
vivo after systemic administration, efficiently transfecting 
neurons and glial cells [65, 66]. Moreover, AAVs are not 
associated with human pathology and thus are reasonably 
safe. The AAV genome is present in the host nuclei in an 
episomal form, and multiple copies can circularize, thereby 
enhancing stability and leading to long-lasting and sustained 
transgene transcription and translation [67, 68]. 
The main studied AAV serotypes are 2, 6, and 9, and while 
they share some features, they differ in others [69]. For instance, 
AAV2 is one of the first and most widely studied, but AAV9 is 
more widely implemented as a therapy due to its ability to cross 
the blood–brain barrier after intravenous administration. AAV9 
appears to transduce glial cells more than neurons, while AAV6 
preferentially transduces neurons [69–71]. Due to their safety 
and efficacy, many AAV gene therapy clinical trials are ongoing 
as described at www.clinicaltrials.gov, namely phase I/II for 
SMA (NCT02122952), Parkinson’s disease (NCT01973543, 
NCT00400634), Alzheimer’s disease (NCT00087789), 
Duchenne muscular dystrophy (NCT00428935), and Leber 
congenital amaurosis (NCT00749957). 
As we mentioned earlier, RNAi molecular therapy repre- 
sents a possible approach to target some of the pathogenic as- 
pects of disease [39]. Gene therapy can be an effective means to 
deliver RNAi molecules as well as to achieve permanent gene 
modulation [71]. AAV can transfer shRNAs, artificial RNAs, or 
miRNAs aimed at gene silencing to the cells. Among these 
strategies, miRNAs represent a natural regulatory mechanism 
through which the cell can regulate its own translation of pro- 
teins. In fact, the so-called interference acts in the cytoplasm on 
the transcribed complementary mRNA ligand, regulating its 
expression [71, 72]. 
A recent in vivo study is of particular interest because it 
provides evidence for a significant delay in disease onset 
and increased survival in a SOD1-G93A rat model by 
targeting mutant SOD1 in upper motor neurons by means 
of an AAV9-shRNA [73]. In general, the use of viral vec- 
tors has made the development of gene therapy against 
mutant SOD1-linked ALS possible, providing encouraging 
  
 
results in several studies in which good tolerability profiles 
were also reported [70, 73,  74]. 
Gene therapy can also be useful for rescuing C9ORF72 
haploinsufficiency or for replacing the RBPs sequestered by 
toxic RNA foci, such as the following: TDP43, FUS, p62, 
Purα, hnRNPA1, hnRNPA1B2, and ADARB2 [16, 75, 76]. 
Additionally, gene therapy can be used to drive the expres- 
sion of regulators to manage foci formation [77]. This is the 
case for MBLN1 overexpression in a DM1 disease in vivo 
model [73] and for Purα in C9ORF72 [78]. 
In the context of a gene silencing therapy, it is possible 
that excessive silencing of C9ORF72 will be incompatible 
with the homeostasis of neuronal cells, so it might be pref- 
erable to consider the so-called combined replacement 
strategy. In this case, non-allele-selective RNAi silencing  
is used to completely knockout the target gene transcrip- 
tion and translation so that the normal allele can subse- 
quently be replaced [77]. A gene therapy approach using 
viral vectors can accomplish both of these tasks. Such a 
therapeutic strategy has been evaluated with a positive out- 
come in vitro, but preclinical in vivo trials are needed to 
address potential problems concerning either silencing and 
gene expression carried out by the replacement strategy or 
viral delivery and transfection. 
The pathogenic elements of C9ORF72 that involve both 
RNA and protein toxicity interact downstream with a large 
number of proteins, enzymes, and messengers, many of which 
have not yet been identified [79]. 
Although some of these pathogenic elements, such as the 
sequestration of RBPs, appear to have a critical role in the 
induction and maintenance of neurotoxicity, it seems unlikely 
that a gene therapy aimed at restoring only a single transcript 
will be able to bring an adequate neuroprotection. Rationally, 
in this context, the targeting of each involved transcript will be 
necessary to establish  neuroprotection. 
Given the plethora of pathogenetic events described, a 
multi-targeted approach that involves different therapeutic 
strategies should be considered. 
Gene therapy may compensate for haploinsufficiency 
and adjust the translation of the toxic RNA, given that 
the effectiveness of the miRNAs in the cells requires the 
presence of preformed machinery, which involves different 
cytoplasmic enzymes [71, 72, 80]. However, an ASO ther- 
apy might be more appropriate to regulate the splicing 
abnormalities [21, 22] that may contribute to C9ORF72 
disease pathogenesis and to provide amelioration of the 
neuropathological features, neuroprotection, and an im- 
proved clinical phenotype. 
Another possible gene therapy strategy to achieve 
C9ORF72 gene correction is the use of the CRISPR/Cas9 type 
II genome editing system that has recently been developed 
against several conditions [81]. CRISPR/Cas9 can be de- 
signed to cut the repeated expansion of the gene by targeted 
homologous recombination. The possibility of achieving a 
specific targeting of the mutant allele resulting in its direct 
correction can be achieved, but it is technically challenging. 
Evaluation of the CRISPR system to determine its therapeutic 
potential for ALS warrants investigation. Adequate methods 
of delivery and cell targeting, safety measures, and treatment 
efficacy are the main goals to pursue and improve in the de- 
sign and implementation of a gene therapy that might lead to 
future clinical trials. 
 
 
Conclusions 
 
The multiple and complex mechanisms involved in ALS 
pathogenesis as well as the undefined wild-type and path- 
ological role of C9ORF72 suggest that a successful thera- 
peutic approach should address many targets and path- 
ways. Furthermore, different challenges have to be over- 
come for the successful implementation of the therapies at 
the preclinical stages. For instance, novel animal models of 
the mutant C9orf72 gene have to be validated and used for 
initial exploration of the therapeutic in vivo effects of the 
lead compounds, besides the use of human cell lines. Most 
of the molecular therapies that we described required the 
implementation of manufacturing technology to  produce 
the amount of product sufficient for large trials and, ulti- 
mately, the treatment of many ALS patients. Finally, suc- 
cessful clinical trials would benefit from reliable bio- 
markers in the design and follow-up. Therefore, C9ORF72 
biomarkers should be further  investigated. 
Until now, the three macro-directions of study that are de- 
scribed in this paper seem to be the most promising and fea- 
sible, although clinical trials are yet to start. The positive re- 
sults obtained in other DNA repeat expansion diseases, such 
as DM1, and the therapeutic success of some of the biomolec- 
ular strategies that we described, such as ASOs and gene ther- 
apy in SMA, are stimulating research to move forward in these 
directions and to share data between researchers investigating 
different diseases and therapeutic approaches. The ongoing 
advances made in the field are encouraging, and further fo- 
cused studies are urgently needed to move them forward even 
faster to deliver an effective cure for patients. 
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